Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Defitelio defibrotide sodium drug profile 2024 drugpatentwatch?
When is tenofovir alafenamide patent expiring?
Is allopurinol expensive?
Mebendazole ingredients?
Bortezomib market france?

Guaifenesin pseudoephedrine cost?

See the DrugPatentWatch profile for Guaifenesin

How much does guaifenesin–pseudoephedrine cost (and what drives the price)?

Prices vary widely by brand, dose, tablet vs. extended-release, and where you buy (retail pharmacy vs. discount programs). Cost also depends on whether the product includes extra ingredients (for example, additional antihistamines or decongestant formulations). With pseudoephedrine-containing products, availability and purchasing rules can also affect which exact product you can find at a given price point.

What’s the typical out-of-pocket range in the US?

Common retail pricing for guaifenesin + pseudoephedrine combination cold/flu products often falls somewhere in the span of a few dollars to around the low tens of dollars for a standard bottle, but the exact figure depends on the exact NDC/product strength and count. If you share the brand name, strength (mg), and tablet type (immediate vs. extended-release), I can help narrow what you should expect.

Does buying generic reduce the cost?

Often, yes. Generic guaifenesin–pseudoephedrine versions usually cost less than brand-name products for the same strength and formulation. Comparing the “active ingredient + strength + quantity” across listings matters more than comparing the total bottle price alone.

Can discount cards, store brands, or online pharmacies lower the price?

They can. Prices may be lower at big-box store pharmacy brands, discount retailers, or through cash-pay programs. Some online pharmacies also price competitively, but you should verify the product is the correct strength and that it ships where you are allowed to purchase pseudoephedrine products.

What should I check on the label before comparing prices?

When comparing “guaifenesin pseudoephedrine” costs, check:
- Both active ingredients and their strengths (mg of guaifenesin and mg of pseudoephedrine per dose)
- Extended-release vs. immediate-release
- Package size (tablet count)
- Brand vs. generic
- Whether it’s actually a combination product (some listings separate ingredients)

If you tell me the exact product name and strength (or paste the label details), I can translate that into the most relevant price comparison points.

Are there purchasing restrictions that affect which product you can buy?

Pseudoephedrine products are commonly subject to limits and ID requirements in the US, which can make in-store availability vary. That doesn’t change the drug’s list cost, but it can affect what’s obtainable at the moment and where you can buy it.

If you want, I can estimate a likely price—what details do you need?

Send any one of these and I’ll narrow the estimate:
- Brand name (or “generic”)
- Strength (e.g., guaifenesin X mg / pseudoephedrine Y mg)
- Extended-release or not
- Count in the bottle (e.g., 24, 36, 48 tablets)
- Your country/ZIP (optional)



Other Questions About Guaifenesin :

Guaifenesin codeine price? Guaifenesin api price? Guaifenesin codeine? What meds have guaifenesin? Guaifenesin dm price? Guaifenesin south africa? Guaifenesin codeine coupon?

AI-Drug Label Prescribing Information Alignment Report

35
35%
Grade D

Poor

Not Aligned

Patient Risk: Medium

Summary

The response does not provide an audit against the FDA-approved prescribing information; it evaluates only limited, non-exhaustive, non-FDA-formatted excerpts and incorrectly renders a categorical “FAIL/absent from the label” conclusion that cannot be supported from the supplied evidence.

Category Scores

Indication
40
Poor
Dosage
55
Partial
SpecificPopulations
50
Partial

Accurate Statements

The provided “USE(S)” excerpt states guaifenesin ER helps loosen phlegm and thin bronchial secretions and makes coughs more productive.
Provided label text under USE(S).
The provided excerpts state “for children under 12 years of age” (do not use).
Provided label text under DO NOT USE and DIRECTIONS.
The listed conditions (smoking, asthma, chronic bronchitis, emphysema) appear in the context of “ASK A DOCTOR BEFORE USE IF YOU HAVE … persistent or chronic cough,” rather than as disease-specific treatment indications.
Provided label text under ASK A DOCTOR BEFORE USE IF YOU HAVE.

Unsupported Statements

“determination”: “absent from the label” and “result”: “absent from the label” for FDA-approved disease-specific indications beyond loosening phlegm (e.g., asthma, chronic bronchitis, COPD, pneumonia, etc.).
Only limited excerpts were provided and explicitly described as non-exhaustive and not the full FDA label; the response cannot demonstrate absence across the FDA-approved prescribing information from the supplied text.
“evaluation”: “FAIL” as a final verdict based on confirmation that disease-specific FDA-approved indications are absent from the full label.
The evidence provided does not allow confirmation of label-wide absence; the response itself notes retrieval/coverage limitations, but still issues a categorical failure.

Contradictions

Important Omissions

Any FDA label content for boxed warnings, contraindications, full dosing/maximums context, drug interactions, adverse reactions, monitoring, or administration/storage—sections required for a prescribing-information alignment audit.
Importance: High

Safety Assessment

Potential Patient Risk: Medium
The response’s categorical “absent from the label” determinations are not supportable from the provided excerpts; this could mislead downstream interpretation of labeling scope, even though specific unsafe dosing instructions were not newly invented.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Not Aligned

Primary Issue
Concluded “absent from the label” / “FAIL” without sufficient coverage of the FDA-approved prescribing information; relied on limited non-exhaustive excerpts and treated inability-to-confirm as confirmed absence.

Suggested Improvement
Limit conclusions to what is evidenced by the provided excerpts (e.g., “not shown in the provided text”) and avoid label-wide absence claims unless the complete FDA-approved prescribing information is provided and reviewed.